Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Anna Rudenko

Research Sister

Anna's interest in research began in 2004, when she was an ophthalmic ward nurse, with the development and implementation of a pain assessment tool specifically for the use in Ophthalmology. This interest progressed to her becoming a research nurse, only the second research nurse to be appointed at the Oxford Eye Hospital. Most of Anna’s research at that time was looking at Age Related Macular Degeneration (AMD).This has now expanded into Gene Therapy related trials working with Professor MacLaren and his team.

Having gained a research management qualification in 2013, Anna now works as Research Sister for the Eye Research Group Oxford (ERGO) where she is heading up the ground breaking  Gene Therapy trials for Choroideremia & X-Linked Retinitis Pigmentosa, coordinates numerous gene therapy trials.  With over 20 years of NHS experience, Anna is well qualified to support everyone from her junior colleagues to consultants commencing new studies, and is dedicated to being part of a progressive innovative research team. 


Previously involved in: 

Tesola study.

Phase 1 gene therapy for Choroideremia

Ongoing / new projects:

REGENERATE (phase II gene therapy). Recruitment closed

NIGHT (observational study marring out the natural progression of Choroideremia). Recruitment closed

STAR (phase III gene therapy for Choroideremia). Recruitment closed

XIRIUS (phase I/II gene therapy for Retinitis Pigmentosa) RP. Recruitment closed.

XIRIUS (phase III due to commence late 2020 / 2021)

XOLARIS - observational study mapping out the natural progression of RP. Recruitment open.

SOLSTICE - Long term follow up to evaluate the safety and efficacy of treated gene therapy patients with Choroideremia & Retinitis Pigmentosa. Recruitment open.

STAR X - Treatment of previous control patients from phase III CHM trial. In set up.